Ikarian Capital, LLC Chemo Centryx, Inc. Put Options Transaction History

Ikarian Capital, LLC

$573 Million
Q3 2024

Put Options

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $11 Million - $24.3 Million	-600,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $4.84 Million - $7.29 Million	-367,600 Reduced 37.99%	600,000 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $4.37 Million - $23.2 Million	455,600 Added 88.98%	967,600 $13 Million
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $2.99 Million - $4.12 Million	60,300 Added 13.35%	512,000 $26.2 Million
Q4 2020 Feb 12, 2021	SELL	$47.25 - $65.16 $2.28 Million - $3.15 Million	-48,300 Reduced 9.66%	451,700 $28 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $19.3 Million - $32.5 Million	500,000 New	500,000 $28.8 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.